The Indian Patent Office has refused to grant a patent for dolutegravir. Dolutegravir is an important anti-HIV drug sold by Viv Healthcare. This will allow generic drugs to enter the market and become affordable. Will help expand access to life-saving treatments. The decision, announced after a contentious battle that lasted nearly a decade, comes after the company filed a patent application for an HIV treatment in 2007.
According to the order seen by TOI, the company faced several pre-grant protests from Natco and various advocacy groups between 2013 and 2019. This led the Patent Office to recently refuse the grant. grant of the patent. Experts believe that this decision could serve as an example against the practice of “evergreen” patents.
A practice that extends the life of patents and improvements to life-saving medications. In the coming years, as more players enter the market, first-line HIV drugs will likely be available at a fraction of the price of innovator drugs. “I am of the opinion that the claims are not patentable under Section 3(d) of the Act as no enhanced therapeutic efficacy has been demonstrated in the specification,” said the order of Assistant Comptroller D Usha Rao.
Viev Healthcare, majority owned by GSK and whose main shareholders are Pfizer and Shionogi. Focuses on HIV treatments. In April 2014, Medicines Patent Pool and VIV Healthcare signed licensing agreements to accelerate access to dolutegravir for adult and pediatric care.
Viev Healthcare, majority owned by GSK and whose main shareholders are Pfizer and Shionogi, focuses on HIV treatments. In April 2014, Medicines Patent Pool and VIV Healthcare signed licensing agreements to accelerate access to dolutegravir for adult and pediatric care.
Check out the health tools below –
Calculate your body mass index (BMI)
